I don't fully agree. The top would be someone like Weizmann but the bottom would never go below the capability of Teva itself. Which is what we have today.
Weizmann is not properly 'tooled' to assist. The "technology" required for the level of complex molecule characterization is far more sophisticated than anything Weizmann can provide.
Market Data 
Markets 
AI
